Public biotechs, ranked by BS score.
Pre-revenue biotechs are uniquely falsifiable: their entire valuation rests on whether one drug works. We extract the core hypothesis from SEC filings, score it against trial design quality, historical base-rates, and language red flags, then publish the result.
tracked
49
scored
46
HIGH
1
MEDIUM
20
LOW
25
| # | ticker | company | score | tier | phase | mkt cap | indication |
|---|---|---|---|---|---|---|---|
| 1 | CBIO | CRESCENT BIOPHARMA, INC. | 61.6 | MEDIUM | PHASE2 | $581.5M | Locally Advanced / Metastatic Solid Tumors |
| 2 | FHTX | Foghorn Therapeutics Inc. | 61.2 | MEDIUM | PHASE1 | $281.2M | Acute Myeloid Leukemia |
| 3 | IMMX | Immix Biopharma, Inc. | 60.4 | MEDIUM | PHASE2 | $516.9M | Solid Tumor, Adult |
| 4 | RAPP | Rapport Therapeutics, Inc. | 58.8 | MEDIUM | PHASE2 | $1.64B | Bipolar 1 Disorder |
| 5 | JBIO | Jade Biosciences, Inc. | 54.8 | MEDIUM | PHASE1 | $899.0M | Healthy Volunteers |
| 6 | SMNR | Semnur Pharmaceuticals, Inc. | 52.8 | MEDIUM | PHASE3 | $1.84B | Lumbosacral Radicular Pain |
| 7 | IRON | Disc Medicine, Inc. | 52.8 | MEDIUM | PHASE3 | $2.57B | Chronic Kidney Diseases |
| 8 | CADL | Candel Therapeutics, Inc. | 52.4 | MEDIUM | PHASE3 | $351.6M | Prostate Cancer |
| 9 | WHWK | Whitehawk Therapeutics, Inc. | 52.0 | MEDIUM | PHASE1 | $167.5M | PROC |
| 10 | BNTC | Benitec Biopharma Inc. | 51.6 | MEDIUM | PHASE2 | $377.1M | Oculopharyngeal Muscular Dystrophy |
| 11 | BDTX | Black Diamond Therapeutics, Inc. | 51.2 | MEDIUM | PHASE2 | $147.8M | Non-Small Cell Lung Cancer |
| 12 | ALLO | Allogene Therapeutics, Inc. | 50.8 | MEDIUM | PHASE2 | $709.4M | Large B-cell Lymphoma |
| 13 | RLMD | RELMADA THERAPEUTICS, INC. | 50.0 | MEDIUM | PHASE3 | $798.2M | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) |
| 14 | LBRX | LB PHARMACEUTICALS INC | 48.0 | MEDIUM | PHASE3 | $753.9M | Schizophrenia |
| 15 | SLS | SELLAS Life Sciences Group, Inc. | 47.6 | MEDIUM | PHASE2 | $906.9M | Breast Cancer |
| 16 | LYEL | Lyell Immunopharma, Inc. | 47.6 | MEDIUM | PHASE3 | $556.4M | Systemic Lupus Erythematosus |
| 17 | EDIT | Editas Medicine, Inc. | 47.2 | MEDIUM | PHASE2 | $282.9M | Blindness |
| 18 | CRDF | Cardiff Oncology, Inc. | 47.2 | MEDIUM | EARLY_PHASE1 | $114.2M | Locally Advanced Pancreatic Ductal Adenocarcinoma |
| 19 | MNPR | Monopar Therapeutics | 46.4 | MEDIUM | PHASE3 | $387.6M | Cancer |
| 20 | TRDA | Entrada Therapeutics, Inc. | 46.4 | MEDIUM | PHASE2 | $537.9M | Mitochondrial Neurogastrointestinal Encephalomyopathy |